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Abstract
With advances in HIV treatment regimens, HIV has become a treatable chronic illness
that requires extensive clinical management (Kelly, Otto-Salaj, Sikkema, Pinkerton, & Bloom,
1998). Nonadherence to HIV medical regimens is a primary reason for treatment failure. HIV
medication regimens are complicated and require extensive time and effort from the patient
(Friedland & Williams, 1999). Since the effectiveness of HIV medication regimens can be severely
limited by poor adherence, much research has been conducted regarding the influence of
psychosocial factors in adherence. However, this research has primarily focused on medication
adherence and has not investigated psychosocial aspects associated with other adherence related
behaviors such as appointment attendance. Thus, the current literature may be missing an entire
group of HIV patients who do not follow through with medical care long enough to receive
medications or other available treatments and services.

The primary purpose of this study was to evaluate the effects of initial coping strategies
on long-term appointment attendance in individuals with HIV. Baseline data collection was
conducted between 1992 and 1995 and included information concerning demographic factors,
illness severity, depressive symptoms, and coping strategies. The current results were obtained
by a retrospective chart review of appointment attendance. It was predicted that problemfocused coping would be associated with attending regularly scheduled clinic visits and emotionfocused coping would be predictive of failure to attend appointments. Multiple regression
analysis revealed that the coping style employed by participants did not predict appointment
attendance above and beyond the variance predicted by demographic, illness, and distress related
factors. However, minority status, depressive symptoms, and history of intravenous drug use did
emerge as reliable predictors of failure to attend scheduled clinic appointments over a three-year
follow-up period. These results suggest that increased depressive symptoms, a history of
v

intravenous drug use, and being African American negatively impact treatment success by reducing
appointment attendance. Further research should evaluate the specific variables associated with

poor appointment attendance among minority individuals.

vi

Introduction
The Human Immunodeficiency Virus (HIV), which leads to Acquired Immunodeficiency
Syndrome (AIDS), has become a worldwide health threat. HIV disease strikes the immune
system and slowly degrades the body’s ability to ward off infections and other illnesses.
Approximately 47 million people have been infected with HIV worldwide (Fan, Connor, &
Villarreal, 2000). Currently, there are about 400,000 people living with HIV or AIDS in the
United States (Center for Disease Control and Prevention [CDC], 1999). Although AIDS-related
deaths are declining, the number of people living with HIV or AIDS continues to increase.
Between 1997 and 1998, there was a ten percent rise in the number of new HIV infections (CDC,
1999). According to the CDC (1999), minorities are disproportionately represented in this
population. Minorities, particularly African Americans, account for 80% of the women and 61%
of the men with HIV. This trend appears to be continuing and emphasizes the importance of
research aimed at effective psychosocial treatments of this rapidly growing population.
HIV is most commonly transmitted through sexual contact and sharing of contaminated
needles. Intravenous drug use is the second highest risk factor for contracting HIV infection
(CDC, 1999; Chitwood, et al., 2000). However, non-intravenous substance use such as crack
cocaine and alcohol also increase the risk of engaging in unsafe sexual behaviors that may
increase exposure to HIV (Stall, McKusick, Wiley, Coates, & Ostrow, 1986). HIV can also be
transmitted from mother to child during pregnancy, birth, or lactation. Although quite rare, HIV
can be transmitted to healthcare workers through accidental needle sticks.
HIV belongs to a class of viruses called retroviruses. Retroviruses encode their genetic
information in RNA rather than DNA and have a complex life cycle. Retroviruses consist of
three main components including a group of core particle proteins, the enzyme reverse
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transcriptase, and a protein coat. Reverse transcriptase allows the virus to replicate and the
protein coat helps the virus bind with other cellular receptors (Fan, et al., 2000). During the
initial infection process, the genetic RNA core of the retrovirus binds with the receptors of
uninfected cells and invades the host cells. Next, reverse transcriptase converts RNA into viral
DNA and is integrated into the cellular machinery. This allows the infected cell, or virion, to
continue functioning normally and the virus to replicate rapidly (Fauci, 1988).
The principle target cell of HIV is T lymphocytes, or T-cells. T-cells contain CD4
protein receptor sites which assist other immune system cells in eliminating foreign particles or
pathogens from the body. HIV binds with these CD4 receptors, thus killing T-cells. As T-cells
are destroyed, immune system functioning declines and infectious agents are not eliminated from
the body. Consequently, illnesses or infections that would rarely survive in the body of a healthy
individual to develop, proliferate, and ultimately lead to the death the infected individual.
The CDC has defined four primary stages of HIV infection. The progression of these
stages varies across individuals. The first phase is an acute HIV syndrome that is sometimes
called seroconversion illness. Individuals may experience vague flu-like symptoms including
fever, fatigue, rash and enlarged lymph nodes. Because these symptoms are nonspecific, people
rarely seek medical attention at this point. The second stage is commonly referred to as the silent
phase and includes a prolonged asymptomatic period that usually lasts between five and ten
years. During the silent stage there is a progressive build-up of the virus in the body (particularly
in the lymph nodes, spleen, and liver) with a concurrent drop in T-cells. The third stage of HIV
infection, the symptomatic phase, is characterized by the presence of noticeable symptoms.
These symptoms include enlarged lymph nodes in the head and neck region, persistent low-grade
fever, night sweats, chronic diarrhea, peripheral neuropathy, and oral ulcers. On average, the
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symptomatic phase lasts approximately three years until an AIDS diagnosis is made. The fourth
stage, AIDS, is marked by the presence of opportunistic infections or cancers (e.g., Kaposi’s
sarcoma) and a T-cell count below 200 cells per cubic millimeter. Without intervention,
opportunistic infections and other illnesses eventually lead to death. However, recent advances
in treatment have dramatically lengthened the symptomatic phase and delayed the onset of AIDS
and eventual death (Kelly, Ott-Salaj, Sikkema, Pinkerton, & Bloom, 1998).
Initially, treatment of HIV/AIDS was limited to the clinical management of the opportunistic
infections that result from HIV infection (Kelly et al., 1998). In the mid 1980's drugs called
nucleoside analogues, such as zidovudine (AZT), were introduced as the first successful
treatment for HIV infection. AZT and other similar drugs (e.g. didanosine, lamivudine) limit the
ability of HIV to produce DNA and thereby decreased the rate of HIV cell replication (Fan et al.,
2000). Although individuals who received these medications experienced some side effects
(headache, nausea, insomnia) they also had fewer opportunistic infections, increased T- cell
counts, and improved survival rates when compared to untreated individuals at a similar stage of
illness (Volberding, et al., 1994).
Between late 1995 and early 1997 a new class of antiretroviral medications called
protease inhibitors was introduced. These drugs prevent the production of HIV by directly
inhibiting the enzyme (protease) responsible for viral maturation, thus slowing the replication of
HIV. Treatment regimens that combine protease inhibitors with at least two other nucleoside
analogues (i.e., combination therapy) have been associated with increased T-cell counts,
decreased levels of HIV circulating in the blood (i.e., viral load), improved health outcomes, and
life extension (Deeks, Smith, Holodniy, & Kahn, 1997; Nelson, 1996). As with the initial
treatments for HIV, the benefits of combination therapy are often limited by side effects. Many
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side effects including fatigue, insomnia, diarrhea, gastro-intestinal discomfort, nausea, and
vomiting are transient and tend to subside within one to two months (Lin-in Tseng, 1998).
However, other side effects such as oral numbness and peripheral neuropathy are more long
lasting and often require medical intervention (Lin-in Tseng, 1998). The success of combination
therapy has also been limited by the complicated nature of the medication regimens. These
regimens require significant time and effort from patients in order to be successful (Carpenter et
al, 2000).
HIV medications must be taken on a demanding schedule and require frequent physician
visits to monitor the patient’s progress and prevent complications. Individuals who are less
adherent with their treatment regimens do not fully benefit from treatment and experience more
opportunistic infections (Montaner et al., 1998; Friedland & Williams, 1999). Although
adherence has been an important factor in chronic illness research in the past, complex HIV
treatments have generated resurgence in this research
Adherence
The importance of adherence in medical regimens is not a new concept. About 25
years ago researchers began to investigate the factors associated with carrying out medical
instructions (Haynes, 1976). Haynes defined medical compliance as the “extent to which a
person’s behavior coincides with medical or health advice” (Haynes, 1976). Presently, the term,
compliance, has fallen out of favor and has been replaced with the term adherence. Instead of
portraying the person as a passive recipient who complies with medical advice, the term
adherence denotes the collaborative, interactional nature of the relationship between individuals
and medical professionals (Turk, Salovey, & Litt, 1986). This definition of adherence
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encompasses a broad array of behaviors including medication intake, appointment attendance
and other health related behaviors.
Adherence in Chronic Illness
Adherence to medical regimens has been studied in a variety of chronic medical
conditions including diabetes, coronary artery disease, and tuberculosis (Epstein, 1984; Friedland
& Williams, 1999; Horowitz et al., 1990; O’Brien, Petrie, & Raeburn, 1992). Adherence rates
among patients with chronic illnesses are surprisingly low and even under ideal conditions rarely
reach 100 percent. It has been estimated that 30% to 60% of patients do not take medications as
prescribed (Augenbraum, et al., 1998; Cramer, Mattson, Prevey, Scheyer, & Oulette, 1989;
Dunbar-Jacobs, Dwyer, & Dunning, 1991). Adherence rates are also low when other health
related behaviors are considered. For example, Gerber (1986) reported that medical
appointments are missed as much as half of the time.
Research has not identified a single variable or group of variables that can reliably predict
who will be adherent with treatment regimens; however, many variables have been linked to
adherence. In general, patient characteristics such as age, gender, ethnicity, and educational
levels have not been shown to be good predictors of adherence, (Besch, 1995; Griffith, 1990;
Meichenbaum & Turk, 1987). However, the most reliable adherence occurs when the illness in
question is short term, and produces obvious disease symptoms (O’Brien, et al., 1992).
Consequently, decreased medication adherence has been associated with complex and longlasting medical regimens that include multiple medications and frequent drug administration,
such as HIV treatments (Griffith, 1990).
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Adherence in Persons with HIV
Research has documented substantial rates of non-adherence with HIV medication
regimens, even during brief periods of time. Early studies of monotherapy estimated that
successful adherence (taking at least 80% of prescribed doses) only occurred approximately 42%
of the time when monitored over the previous month (Singh et al, 1996) and 67% of the time
when monitored over the previous week (Samet et al., 1992). Similar results have been noted
studies of adherence to combination regimens. Hecht, Colfax, Swanson, & Chesney (1998)
found that outpatients at an AIDS clinic in San Francisco reported missing 20 percent or more of
their HIV medications over a short three-day period. This is consistent with other results
regarding combination therapy including a study by Catz and colleagues that found that one third
of patients reported missing medication doses within the past five days (Catz, Kelly, Bogart,
Benotsch, & McAuliffe, 2000). Because poor treatment adherence represents a major problem
facing individuals with HIV and substantially impacts the effectiveness of their treatment, much
research has been conducted to investigate the factors associated with HIV treatment adherence.
These variables can be divided into two main categories: HIV treatment characteristics and
individual characteristics.
HIV Treatment Characteristics
In general, research has shown that medical regimens are more likely to be followed
when the disease is brief, treatment regimens are simple, and the medication removes salient
symptoms (Agras, 1989; Blackwell, 1992; Nannis, Temoshock, Smith, & Jenkins, 1993).
Additionally, complicated treatment regimens that involve large numbers of medications with
difficult dosing requirements and troublesome side effects have been associated with
nonadherence (Dunbar-Jacobs, et al., 1991). Because HIV infection is a chronic illness that does
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not always produce overt symptoms and involves a complex and demanding course of treatment,
the HIV medication regimens that are currently available have not proven to be representative of
the ideal conditions to promote adherence (Friedland & Williams, 1999).
Individual Characteristics
HIV medication adherence is best when the individual is educated about the treatment
(Eldred, Wu, Chaisson, & Moore, 1998; Stall et al., 1996), believes the treatment is needed
(Blumenfield, Milazzo, & Wormser, 1990), has support from family and friends, (Mostashari,
Riley, Selwyn, & Altice, 1998; Singh, et al., 1999; Stall et al, 1996), and is convinced of
treatment efficacy (Catt, Stygall, & Catalan, 1995; Muma, Ross, Parcel, & Pollard, 1995).
As with other illnesses, initial research showed that demographic variables such as age,
gender, and education level were not good predictors of adherence to HIV medication treatments
(Muma et al., 1995; Singh, et al., 1996). However, many of these studies included samples that
consisted of primarily Caucasian homosexual males. Other studies, that have included broad
samples more representative of the entire population of individuals with HIV, have shown
demographic factors, particularly ethnicity, are predictive of decreased adherence (Eldred, et al.,
1998; Singh, et al. 1996; Singh et. al, 1999). For example, Singh and colleagues (1999) found
that 31% of Caucasians were adherent with medication regimens, but only 12% of minority
participants (predominately African-American) followed their medication regimens.
Demographic differences are even stronger when the definition of adherence is broadened to
include variables such as appointment attendance (Catz, McClure, Jones, & Brantley, 1999;
Israelski, Gore-Felton, Power, Wood, & Koopman, 2001; Kissinger, 1995; McClure, Catz, &
Brantley, 1999). Given the current increased incidence of HIV among the minority population,
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understanding these ethnic differences and related psychosocial factors is especially important
(CDC, 1999; CDC, 2000).
Other individual variables have been found to negatively impact adherence.
Psychological difficulties have been associated with decreased appointment attendance,
particularly when depressive symptoms or substance use is involved (Catz et al., 1999;
O’Connor, Selwyn, Schottenfeld, 1994). Each of these factors will be reviewed briefly below.
Depressive Symptoms: Individuals with HIV may be at a greater risk for experiencing
depressive symptoms due to the stressors associated with living with a fatal and stigmatizing
illness. Depression is a common problem among individuals with HIV. It is estimated that 20%
of individuals with HIV/AIDS experience depression (Heckman, Kochman, Sikkema, &
Kalichman, 1999). Depression can seriously impact patients overall well-being and adherence to
their medical regimens.
Studies have shown that HIV patients who experience increased depressive symptoms
demonstrate poor adherence, report more pain, have lower T-cell counts (i.e., indicating greater
illness), and increased substance use compared to HIV patients with average levels of depressive
symptoms (Blumenfield, et al., 1990, Bogart, et al., 2000, Catz, et al., 2000; Kalichman,
Ramachandran, & Catz, 1999; Rabkin,& Ferrando, 1997; van Servellen, Sarna, Padilla, &
Brecht, 1996.; Vassend & Eskild, 1998). Furthermore, depression has been linked to poor health
outcomes in individuals with HIV including increased progression of HIV to AIDS and
increased mortality (Ironson et al., 1994; Leserman, et. al, 2000; Mayne, Vittinghoff, Chesney,
Barrett, & Coates, 1996; Page-Schafer, Delorenze, Satariano, & Winkelstein, 1996).
Substance Abuse: A large number of individuals with HIV who have a history of substance use
may continue using illicit drugs while receiving treatment for HIV. Substance abuse may lead to
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problems with treatment adherence and ultimately treatment failure. Substance use has been
linked to poor adherence and may lead to increased viral progression (Dickinson, 1998;
Haubrich, et al., 1999; O’Connor et al, 1994; Samet et al., 1992). Eldred and his colleagues
(1998) found that HIV patients cited problems associated with the use of drugs and alcohol as the
third most common reason for missing HIV medications. Substance use is also important in
adherence behaviors not directly related to medication intake. For example, substance use has
been consistently identified as a primary risk factor in missed clinic appointments (Kissinger, et
al., 1995; McClure, et al., 1999). Consequently, many individuals who have a history of
substance use may be at risk for dropping out of treatment entirely. Little research exists that
help explain the role of substance abuse in adjustment to HIV treatment demands.
Coping strategies have been shown to be useful in helping individuals manage the
psychosocial stressors associated with HIV (Chesney, Folkman, & Chambers, 1996; Siegel,
Gluhoski & Karus, 1997). The strategies individuals use to cope with HIV treatment are an
important mental health issue because these strategies ultimately influence treatment success
(Kelly et al, 1998). Recent studies have also shown that the coping strategies individuals use to
adjust to HIV, may impact their participation in treatment.
Coping
Coping involves cognitive and behavioral efforts to manage problems caused by stressful
situations. Lazarus and Folkman (1984) defined coping as a dynamic process based on an
individual’s appraisal of the extent to which the stressor outweighs their psychological resources.
Coping includes adaptive efforts to manage the external or environmental aspects of a stressor,
and avoidant behaviors to minimize exposure to the stressful situation (Lazarus, 1993). Coping
strategies can be divided into two broad categories: problem-focused coping and emotion-
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focused coping (Bombardier, D’Amico, & Jordan, 1990). Problem-focused coping is aimed at
managing the external or environmental aspects of a stressor. In contrast, emotion-focused
coping is aimed at regulating the affective consequences of a stressor. Examples of problemfocused coping in HIV include becoming active in one's medical regimen such as seeking out
information about HIV, and making healthy lifestyle changes. Examples of emotion-focused
coping include avoidance and distraction including refusing to discuss HIV and attempting to
forget about being HIV positive by not attending medical appointments (Kalichman, 1998).
Reliance on emotion-focused coping strategies has generally been associated with poor
adaptation to stressors (Moos & Schafer, 1993).
Studies have shown that individuals with HIV who utilized problem-focused coping
experience less psychological distress than those patients who utilized emotion-focused
strategies such as avoidance (Namir, Wolcut, Fawzy, & Alumbaugh, 1987; Nicholson & Long,
1990; Siegel, et al., 1997; Wolf, et al., 1991). For example, Namir and her colleagues (1987)
found that increased depression was associated with emotion focused coping in a group of men
living with HIV/AIDS. Emotion focused coping has not only been associated with depression,
but also with increased disease progression. While, increased utilization of active coping
strategies has been associated with reduced severity of HIV symptoms (Mulder, Antoni,
Duivenvoorden, Kauffmann, & Goodkin, 1995; Solano, et al., 1993). Problem-focused coping
strategies have also been related to increased quality of life ratings and improved medical
outcomes, including increased CD4 counts, for individuals with HIV (Friedland, Renwick, &
McColl, 1996; Goodkin, et al., 1992).
Many studies have noted ethnic differences in coping and psychosocial adjustment. In
general, minorities tend to utilize emotion focused coping strategies rather than problem-focused
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coping strategies (Plummer & Slane, 1996; Slavin, Rainer, McCreary & Gowda, 1991). These
results have also been confirmed in medical populations (Rodrigue, 1997). However, there are
mixed results concerning the role of ethnicity on coping strategies and subsequent adjustment to
living with HIV (Heckman, et al., 1999; Lesserman, Perkins, and Evans, 1992; Singh et al.,
1999).
Lesserman and colleagues (1992) found that found that African American men with HIV
expressed increased depressive symptoms and utilized more emotion focused coping strategies.
These results were confirmed in a larger multi-site study (Singh, et al., 1999). However,
Heckman and colleagues (1999) came to the opposite conclusion, finding that a group of African
American men demonstrated increased problem-focused coping and decreased depression. The
mixed results concerning coping style and subsequent psychological distress among ethnic
minorities may have been caused by the use of restricted samples. The above-mentioned
research was conducted with homosexual male participants and may not be representative of
other individuals with HIV. Since rates of new HIV infections are rising fastest in the AfricanAmerican population and this population is confronted with many economic and cultural issues
that complicate their adjustment to HIV, identification of potential variations in coping style is
necessary. Furthermore, the impact these coping strategies have on adherence may lead to the
development of behavioral interventions (e.g., coping skills training) that would be helpful in
improving overall quality of life for minority individuals (CDC, 1999).
The Impact of Coping on Adherence
The strategies individuals use to adjust to the stressors associated with living with HIV
disease may significantly impact whether these individuals fully participate in treatment.
However, few studies have investigated the role of coping in adherence to HIV treatment. Singh
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and colleagues found that individuals, who reported increased utilization of problem-focused
coping demonstrated increased adherence to HIV medications when compared to individuals
who utilized emotion-focused coping (Singh et al., 1996; Singh, et al., 1999). Other studies
have also noted the importance of problem-focused coping (e.g. educating oneself about the
disease and its treatment) in successful adherence to HIV medication regimens (Freeman,
Rodriguez, & French, 1996; Kissinger, et al., 1995). Although coping appears to impact
medication adherence, there is little information available about the role of coping strategies in
other behavioral aspects of adherence, such as appointment attendance.
Limitations in the Current Adherence Literature
Most of the information we have concerning adherence to HIV treatment regimens is
limited to medication intake, and may be neglecting many other important aspects of adherence.
There are numerous behaviors associated with adherence including appointment attendance.
Relatively few studies have examined these behavioral aspects of adherence to HIV treatment
regimens. This is unfortunate as these behaviors are necessary to ensure successful treatment. In
order to reduce drug resistance to the current medication regimens, the current HIV treatment
guidelines dictate that patients not be placed on medication until they demonstrate significant
progression of HIV related symptoms. Thus, it is even more important that patients attend clinic
visits for monitoring. Patients must also attend medical appointments in order to receive any
medical advice or prescriptions. Once patients have started HIV medication regimens, frequent
physician and nurse visits are required to ensure the medications are being taken as prescribed,
gauge the success of the treatment regimen, and to prevent complications. Consequently, nonattendance to medical appointments can seriously interfere with treatment success.
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Recent evidence has demonstrated the importance of not limiting the scope of adherence
to medication intake, thus neglecting other important aspects of adherence. Lucas, Chaisson, &
Moore (1999) identified missed appointments as the primary risk factor to HIV treatment failure
at a large inner city HIV clinic. Other studies have shown that variables that are not traditionally
important in medication adherence may be important in appointment attendance. For example,
Kissinger (1995) found that patients who were most likely to miss appointments were African
American, and had a history of IV drug use. Other studies have found similar results with
minority status and drug use history emerging as reliable predictors of appointment nonattendance (Catz, et al., 1999; Israelaski, et. al., 2001; McClure, et al., 1999). Israelaski (2001)
and colleagues found that appointment non-attendance was highly associated with heterosexual
African Americans. This study included only demographic variables and accounted for 13% of
the variance in appointment attendance. This suggests that variables other than demographic
characteristics may also be involved in missing clinic appointments (Catz et al., 1999; McClure
et al., 1999). The current study evaluated the impact of demographic variables, distress related
factors, and coping style on appointment attendance.
Summary
Advances in HIV treatment regimens have dramatically changed the long-term prognosis
for people diagnosed with HIV. When combination therapies were introduced, overall mortality
and new AIDS cases declined for the first time since the beginning of the HIV/AIDS epidemic
(CDC, 1999). Thus with new treatments, HIV has become a treatable chronic illness that
requires extensive clinical management (Kelly et al., 1998). These medical regimens require
significant time and effort from patients including frequent physician contact to monitor the
course of the disease, determine appropriate treatments, and ensure the success of these
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treatments. As with other chronic illnesses, many individuals have difficulty following medical
recommendations and fail to attend medical appointments on a regular basis (Hecht, et al., 1998,
Kissinger, 1995, Lucas et al., 1999). Much of the current literature on HIV adherence involves
medication adherence and may be missing an entire group of HIV patients who do not follow
through with medical care long enough to receive medications or other available treatments and
services. Consequently, investigating factors that might be indicative of future likelihood of
returning to treatment and can be easily obtained during initial contact with each patient is
necessary.
Given the importance of attending medical appointments in successful clinical
management of HIV, the present study attempted to identify important psychosocial and illnessrelated variables that would reliably predict appointment attendance. The primary purpose of the
study was to determine if coping styles used by individuals with HIV would predict whether
patients reliably attended scheduled medical appointments on a long-term basis. Demographic
factors (ethnicity, age, education, sexual orientation), illness severity (T-cell counts, symptom
counts), and coping style (emotion-focused vs. problem-focused) were explored among a group
of outpatients at an outpatient HIV medical clinic. Specifically, the study addressed the
following hypotheses:
Hypothesis 1) It was hypothesized that coping style (problem-focused vs. emotionfocused) would predict appointment attendance above and beyond the variance predicted by
demographic (ethnicity, age, gender, sexual orientation, education), illness related (symptom
counts, T-cell counts), and distress related factors (depression, substance abuse). Problemfocused coping is characterized by actively managing aspects of a stressor, such as participating
in ones treatment regimen; whereas, emotion-focused coping is characterized by emotional
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responses including avoidance and re-appraisal of the stressor (Kalichman, 1998). Problemfocused coping has been consistently associated with improved adjustment to HIV related
stressors, improved medical outcomes in HIV, and improved adherence to HIV medication
regimens. Consequently, problem-focused coping was expected to be predictive of reliable
appointment attendance (Friedland et al., 1996, Goodkin et al., 1992; Siegel, et. al, 1997; Wolf
et. al, 1991). On the other hand, emotion-focused coping has been associated with increased
psychological distress, complicated adjustment to HIV, and increased disease progression
(Mulder et al., 1995, Soiano et al., 1993). Thus, emotion-focused coping was expected to be
predictive of nonattendance to clinic appointments.
Hypothesis 2) It was hypothesized that demographic factors, particularly ethnicity, would
impact coping style. Specifically, minority individuals were expected to utilize more emotionfocused coping strategies, while their Caucasian counterparts were expected to utilize more
problem-focused coping strategies. In general, the literature concerning ethnic differences in
coping has shown that minority individuals demonstrate increased use of emotion-focused
coping strategies (Plummer & Slane, 1996; Rodrigue, 1997; Slavin, Rainer, McCreary & Gowda,
1991). However, this finding has not been consistent in adjustment to HIV related stressors
(Heckman, et al.,1999; Lesserman, et. al, 1992; Singh et al., 1999). The majority of this research
has been conducted with restricted samples that consisted of male research participants. The
sample of participants in the current study was more balanced and provided a good opportunity
to evaluate the effects of ethnicity on coping with HIV related stressors. Since emotion-focused
coping has been associated with increased distress (Namir et al., 1987; Nicholson & Long, 1990;
Siegel et al, 1997, Wolf, et al., 1991) minority participants were also expected to report increased
depressive symptoms.
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Hypothesis 3) It was hypothesized that participants with a history of substance abuse
would utilize emotion-focused coping strategies more than problem focused coping strategies.
Specifically, it was expected that participants with a history of substance abuse would utilize
significantly more avoidant coping than participants who had no history of substance abuse. In
other populations, increased use of avoidant coping has been noted in individuals with a history
of substance use (Avants, Warburton, & Margolin, 2000; Belding, Iguchi, & Lamb, Lakin, &
Terry, 1996), but relatively little research exists about the relationship between coping strategy
and history of substance use in individuals with HIV.
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Methods
Participants
Volunteers were recruited during their medical appointments at an ambulatory care HIV
clinic (Early Intervention Clinic) located at Earl K. Long Medical Center (EKL). This public
teaching hospital in Baton Rouge, Louisiana is part of the Louisiana State University Medical
School Campus and serves primarily low SES and uninsured individuals. EKL Patients rarely
utilize HIV services outside of this clinic. Volunteers were eligible to participate in the study if
they were able to read and were at least 18 years of age. One hundred and sixty patients
completed initial baseline evaluation. Outpatient appointment attendance was obtained for a
period of three years following completion of the baseline evaluation for each of these
individuals. The participants were predominately low income (mean yearly income= <$10,000
per year) minority (African American= 65%), males (60.6%). The mean age was 32 (SD= 7.9)
years and mean education level was 12 years (SD=2.3). Thirty five percent of the sample
endorsed intravenous drug use. Approximately 64% of the sample was heterosexual, while 36%
were homosexual. The homosexual participants were predominately male as only one female
identified as homosexual. Only 12.5 % of the minority participants identified as homosexual.
Twenty-eight percent of participants were “asympotmatic” (T-cell count >500); 41% were
“symptomatic” (T-cell count 200-500); and 24% were diagnosed with AIDS (T-cell count <
200).
Measures
Demographics Questionnaire
A questionnaire concerning demographics and other information important to the population
was administered (See Appendix A). The form includes questions concerning age, gender, race,

17

education level, marital status, drug and alcohol use, and sexual preference. This information
was also obtained by a review of the patient’s medical record.
Appointment Adherence
Appointment adherence data were obtained by conducting a retrospective chart review of
each patient’s Early Intervention Clinic medical record(s). Written records of each scheduled
nurse or physician visit at were located and recorded. Each scheduled clinic visit was
documented as to whether the patient attended, canceled, or missed (i.e., missing the
appointment without canceling or rescheduling, “no shows”) the appointment. This information
was then used to calculate the total percentage of appointments attended during the three-year
period. The following formula was used:
Appointments Attended
Appointments Attended
+
Appointments No-showed or Canceled
Frequency of appointments scheduled may vary over time due to factors such as the patient’s
health status, the patient relocating, or the physicians scheduling availability. Consequently, the
percentage of appointments attended was used rather than frequency of appointment attendance.
When patients are in good health, appointments may only be scheduled every three to six
months. In order to allow the number of scheduled appointments to stabilize and to investigate
the long-term impact of initial coping strategies, attendance data were collected for a total period
of three years.
Ways of Coping Questionnaire Adapted for HIV
The Ways of Coping Questionnaire (WCQ) is a 66-item scale designed to measure cognitive
and behavioral coping strategies people use to manage their reactions to stressful events
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(Folkman & Lazarus, 1988). The WCQ questionnaire accounts for the dynamic nature of the
coping process while also assessing tendencies toward problem-focused or emotion-focused
coping.
During administration of the WCQ participants were instructed to recall the most
stressful situation related to being HIV positive they experienced in the past week. Next, they
were asked to rate the extent to which they used certain coping strategies during this stressful
encounter. The response format is a four-point Likert scale that ranges from 0 (not used) to 4
(used a great deal). Factor analysis of the WCQ revealed eight coping scales including 1)
confrontive coping, 2) distancing, 3) self-controlling, 4) seeking social support , 5) accepting
responsibility, 6) escape-avoidance, 7) planful problem solving, and 8) positive reappraisal
(Folkman & Lazarus, 1988). The planful problem solving scale is representative of problemfocused coping; whereas, six of the other scales are representative of emotion-focused coping
(distancing, self controlling, accepting responsibility, escape-avoidance, confrontive coping, and
positive reappraisal). The seeking social support scale contains both problem-focused and
emotion-focused coping items and cannot be considered to be indicative of a single form of
coping. See Appendix B for a description of these coping scales. These scales can be
considered separately or combined to obtain a total coping score (Folkman & Lazarus, 1988).
The WCQ has demonstrated good reliability and validity. The items were originally
obtained by having individuals list the coping strategies they use in stressful situations. The
authors consider this to be evidence of face validity. Construct validity was established by
demonstrating congruence between theoretical predictions and research supporting coping as a
process that consists of both problem-focused and emotion-focused strategies (Folkman &
Lazarus, 1980; Folkman, Lazarus, Dunkel-Schetter, DeLongis, & Gruen, 1986; Folkman &
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Lazarus, 1988). Due to the dynamic nature of the coping process, traditional test-retest
reliability statistics are not provided. However, the authors reported measures of internal
consistency with alpha coefficients ranging from .79 (Positive Reappraisal) to .61 (Distancing).
The WOC questionnaire has been used successfully in research regarding coping with a variety
of chronic illnesses including HIV (Namir, et al., 1987; Singh, et al., 1996).
Center for Epidemiological Studies Depression Scale (CES-D)
The CES-D is a 20-item self-report depression inventory that emphasizes the cognitive
aspects of depression rather than somatic complaints(Radloff, 1977). Consequently, the CES-D
is ideal for use with medical populations. Individuals rate the frequency of depressive
symptomology over the past week. The response format is a four point Likert scale that ranges
from 0 (none of the time) to 3 (most or all of the time). Total scores range from 0 to 60 with
scores above 16 indicating the presence of depression. Higher scores are indicative of increased
depressive symptoms.
Substance Abuse
Substance abuse was measured in the following manner. First, substance abuse history
was established via interviews with the patients during their initial appointments with at the HIV
clinic. The presence of substance abuse was documented from progress notes made during each
clinic visit. This information was used to obtain a measure of current substance abuse. Current
substance abuse was defined as the presence (as indicated by medical record) of substance abuse
during the three year time period.
Illness Severity
As discussed above, the principle target cell of HIV includes T-cells. Thus, a good and
reliable measure of illness severity can be obtained by collecting absolute T-cell counts from
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blood draws. Baseline T-cell counts were obtained through a chart review of routine laboratory
reports. These T-cell counts were used as an index of illness severity. Additional information
concerning illness severity was obtained by collecting baseline symptom counts. Baseline
symptom counts are routinely collected during medical intake as a measure of illness severity.
Increased symptoms occur with more progressed HIV infection and indicate greater illness (Fan
et al., 2000). Symptom counts can range from 0 to 20. See Appendix C for a list of pertinent
symptoms included in this count.
Procedure
Attendance information the current study was obtained through a retrospective review of
the participants’ medical records. Baseline data collection occurred between 1992 and 1995.
Volunteers were consecutively recruited during their initial appointments with the HIV
outpatient clinic. Participants included individuals who had been diagnosed with HIV and were
receiving outpatient medical treatment at the above-mentioned clinic (EKL). Informed consent
was obtained prior to participation in the study (see Appendix D). Demographic information
was obtained from patient interviews conducted during the initial clinic appointment and from
the baseline demographics questionnaire completed by patients. Information concerning disease
status and other medical information was obtained through a review of the patients’ medical
records at baseline. Participants were paid five dollars for completion of the baseline
questionnaires.
Following baseline data collection all scheduled clinic appointments, including physician
and nurse visits, were monitored via chart reviews for a period of three years from the patient’s
entry into the study. Appointment attendance information (frequency of scheduled, canceled,
and “no show” appointments) was obtained from a retrospective review of the patients’ medical
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records. When available, other important information such as changes in attending physician
and reason for discharge from the clinic (e.g. deceased, relocating) was also recorded during
examination of the patients’ medical records.
Research Design
A retrospective review of the medical records was conducted in order to determinethe
frequency of participants’ appointment adherence on a long-term basis. The primary focus of
the study was to determine the predictive value of coping strategies on appointment attendance
above and beyond demographic factors, illness severity, and distress variables (substance abuse,
depression). Participants completed baseline data and their medical attendance was tracked for a
period of three years. As to maximize predictive validity over time, only individuals who
completed the three years of treatment and did not drop out for any reason (e.g., death relocation,
lost to follow-up) were included in the multiple regression analysis. Analysis of individuals who
were classified as “attenders” and “nonattenders” was conducted on an annual basis.
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Results
Analysis of Demographic Data
A total of 160 participants completed baseline evaluation measures. Appointment
attendance was retrospectively tracked over a three-year period. Three years following intake,
83 individuals remained in treatment at the clinic. Clinic appointments are often scheduled on an
irregular basis and appointments may be scheduled as few as three to four times yearly.
Consequently, attempts were made to maximize predictive validity in the current study and only
individuals who completed the three years of treatment and did not drop out for any reason (e.g.,
death relocation, lost to follow-up) were included in the multiple regression analysis. Although
this procedure introduces a selection threat to validity, the data set remained strong and did not
suffer greatly due to this selection bias. Demographic characteristics of the two samples were
very similar and no significant differences occurred between the two samples. A comparison of
the total sample (N=160) and the sample included in the regression analysis (N=83) is presented
in Table 1. Analysis of the regression residuals also reveals an approximate normal distribution.
These results can be found in Figure 1.
The regression sample consisted primarily of African American males with an average of 12
(SD=2.36) years of education. The average age of the participants was approximately 33
(SD=7.83) years old.
Means and standard deviations were computed for the independent variables of interest
including T-cell counts, symptom counts, CES-D scores, and for each of the WCQ scales. These
results can be found in Table 2. On average participants reported relatively few HIV symptoms
and T-Cell counts above the level required for an AIDS diagnosis. Thus, most of the sample did
not exhibit symptoms associated with severe illness. The sample reported increased depressive
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symptoms, as the mean score on the CES-D (M=21.89) was above the score, which is indicative
of elevated depressive symptoms (16).
Table 1. Sample Comparison: Demographic Characteristics
Total Sample
(N=160)

Regression Sample
(N=83)

Variable

N

%

N

%

Gender
Male
Female

97
63

60.6
39.4

48
35

57.8
42.2

104
53
3

65.0
33.1
1.9

32
51

38.6
61.4

Orientation
Heterosexual
Caucasian
Minority
Male
Female
Homosexual/Bisexual
Caucasian
Minority
Male
Female

102
17
83
41
61
57
36
20
56
1

63.8
10.6
51.9
25.6
38.1
35.6
22.5
12.5
35
.63

50
9
41
16
34
33
23
9
32
1

60.2
10.8
49.4
19.3
41.0
39.8
27.7
10.8
38.6
1.2

IV Drug Use History
Caucasian
Minority
Male
Female

56
14
41
39
1

35.0
8.8
25.6
24.4
.6

24
7
17
18
6

28.9
7.4
20.5
21.7
7.2

Ethnicity
Caucasian
Minority
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Table 2. Descriptive Statistics of Study Completers
Variable

M

(SD)

Range

2.30

(2.37)

0-13

T-Cell Count

422.02

(296.35)

30-1554

CES-D

21.89

(13.04)

0 – 55

WCQ
Confrontive
Distancing
Controlling
Seeking Social Support
Accepting Responsibility
Escape-Avoidance
Planful Problem Solving
Positive Reappraisal

7.24
9.63
12.02
9.90
6.07
11.78
9.80
13.30

3.95
3.95
3.87
4.21
2.95
4.99
4.20
4.87

0-16
1-17
2-20
0-18
0-12
0-23
2-21
2-21

Symptoms

Pearson correlations were computed to examine possible significant relationships
between demographic factors, illness severity factors, depression, and total percentage of
appointments attended. Increased education was significantly correlated with fewer depressive
symptoms on the CES-D. Total attendance was negatively correlated with T-cell counts and
depressive symptoms. The correlation matrix of demographic and medical variables is located in
Table 3. As expected each of the WCQ scales were significantly intercorrelated, indicating that
the current participants interpreted the WCQ in a similar fashion to the validation sample. These
results can be found in Table 4.
Significant correlations were also noted between the CES-D and several emotion-focused coping
scales of the WCQ including confrontive (r (80) = .43, p< .01), distancing (r (80) = .26, p< .05),
self-controlling (r (80) = .30, p< .01), accepting responsibility (r (80) = .48, p< .01), and escapeavoidance (r (80) = .47, p< .01). Education was negatively correlated with the confrontive (r
(83) = -.31, p< .01), seeking social support (r (83) = -.24, p< .05), and escape avoidance (r (83) =
-.26, p< .05) subscales of the WCQ. Total percent attendance was negatively correlated with
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emotion-focused scales of the WCQ including confrontive (r (83) = -.42, p< .01), self-controlling
(r (83) = -.26, p< .05), accepting responsibility(r (80) = -.33, p< .01), and escape-avoidance (r
(83) = -.23, p< .05).
Table 3. Correlation Matrix: Demographic and Medical Variables
1. Age

1

2

3

4

5

6

-

.42

-.07

-.10

-.03

.18

-

-.14

-.12

-.24*

.17

-

-.05

.10

-.04

-

-.04

-.23*

-

-.30**

2. Education
3. Symptoms
4. T-Cell Count
5. CES-D
6. Total % Attendance

-

*p<.05
**p<.01
Table 4. Correlation Matrix: Intercorrelations among WCQ Scales
1. Confrontive
2. Distancing
3. Self-Controlling

1

2

3

4

5

6

7

8

-

.47**

.50**

.48**

.61**

.62**

.42**

.29**

-

.51**

.24*

.52**

.61**

.45**

.37**

-

.33**

.56**

.56**

.53**

.52**

-

.35**

.29**

.44**

.52*

-

.59**

.52*

.34**

-

.37**

.26*

-

.58**

4. Seeking Social Support
5. Accepting
Responsibility
6. Escape-Avoidance
7. Planful Problem Solving
8. Positive Reappraisal

-

*p<.05
**p<.01
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T-tests were computed to determine the presence of any significant group differences
between gender, ethnicity, and participants with a history of intravenous drug use on illness
related factors, coping strategies, or total percentage of appointments attended. A Bonferroni
correction was used to control for the overall error rate associated with performing multiple ttests. An adjusted significance level of .004 was used for the following analyses. Results
indicated that females (M=545) demonstrated significantly higher T-cell counts (t (47) = 2.98, p
= .004) than males (M=338). Females (1.43) also demonstrated fewer HIV related symptoms (t
(78) = -3.05, p = .003) than males (M=2.98). When compared to Caucasians (M=309),
minorities (M=495) demonstrated higher T-cell counts (t (74) = -3.22, p = .002). Minority
individuals (M=66.8%) also demonstrated significantly decreased percentage appointment
attendance (t (79) = 4.39, p < .001) when compared to Caucasians (M=82%). Minoritiy
participants (M=14.47) utilized more of the emotion focused coping technique, positive
reappraisal (t (80) = -2.88, p = .004) than Caucasian participants (M=11.41). Participants who
reported a history of intravenous drug use (M=9.79) were more likely to use confrontive ways of
coping (t (80) = -4.16, p < .001) than participants with no prior drug use history (M=6.14).
Analysis of Total Attendance
A wide range of variability was noted in the attendance data, indicating that range
restriction did not limit the validity of the current data set. The average attendance (N=107) for
the total three-year period was 70% with scores ranging from 0% to 100%. Average attendance
for year one (N=160) was 71 % (range= 0-100), year two (N=104) was 66% (range= 0-100), and
year three was 65% (range = 0-100). As mentioned above, total percentage attendance was
significantly and negatively correlated with T-cell counts and depression.
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Analysis of Coping and Attendance
Correlational analysis was conducted to determine the strength of association between
coping strategies and total attendance. Total percentage attendance was significantly and
negatively associated with emotion focused coping strategies including confrontive (r (96) = .31, p = .001), self-controlling (r (97) = -.23, p = .02), accepting responsibility (r (97) = -.27, p =
.005), and positive re-appraisal (r (97) = -.23, p = .02). The relationship between coping and
appointment attendance was also evaluated on an annual basis. Only one emotion-focused
coping strategy remained significantly correlated with appointment attendance for each of the
three years and total percentage attendance. Confrontive coping was significantly associated
with appointment attendance in year one (r (155) = -.20, p = .02), year two (r (104) = -.23, p =
.02), and year three (r (96) = -.24, p = .02). Distancing (r (156) = -.25, p = .002), self-controlling
(r (156) = -.22, p = .005), and escape-avoidance, (r (156) = -.16, p = .05) was significantly
associated with attendance in year one. Accepting responsibility was significantly correlated
with attendance in year one (r (156) = -.17, p = .04) and year two (r (104) = -.26, p = .009).
Proportional data are particularly susceptible to skewness and may not be normally
distributed (Cohen & Cohen, 1983). The procedure for determining if a score transformation is
appropriate for a data set that was suggested by Cohen & Cohen (1983) was conducted with the
current data set. Residual scatterplots were examined for linear irregularities. The data for total
percent attendance did not require score transformations, as the data approached a normal
distribution that was significantly disrupted by a score transformation. See Figure 1 for the
histogram of regression residuals.
Regression analysis was conducted to explore the effects of coping on appointment
attendance using a hierarchical regression procedure. In order to control for variables that may
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significantly impact attendance, these variables (i.e., age, sex, race, education, sexual orientation,
HIV related symptoms, T-cell counts, intravenous drug use, and CES-D scores) were entered in
the first block of the regression model as a set. For the second block, emotion focused coping
scales (confrontive, distancing, self-controlling, accepting responsibility, escape-avoidance,
positive reappraisal, seeking social support) were entered in a stepwise fashion. Finally,
problem-focused coping (planful problem solving) was entered in the third block in a stepwise
fashion.
10
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Frequency of Attendance

6
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2

0
-2.25

-1.25
-1.75
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Standardized Regression Residual

Figure 1. Histogram of Regression Residuals
The overall regression model did not support the hypothesis that coping skills would
predict variance in long-term appointment attendance beyond the level of prediction offered by
demographic and distress related (CES-D, intravenous drug use) variables. The regression
model revealed that minority status (Beta = -.25), intravenous drug use (Beta = -.36), and
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depression (Beta = -.23) were highly associated with appointment attendance (R2 (9, 64) = .30, p
< .001). Analysis of squared semipartial correlation coefficients indicate that intravenous drug
use accounted for the most variance (8%) with ethnicity and depressive symptoms accounting for
4% of the variance in appointment attendance. See Table 5 for a summary of the hierarchical
regression analysis. Post-hoc power analysis was conducted following the procedure suggested
by Cohen (1992) and a moderate degree of power (.72) was estimated.
Table 5. Multiple Regression Analysis: Coping and Appointment Adherence
Squared

Variable

∃

t

Semipartial
Correlation

Age

.19

1.79

.03

Gender

.23

1.45

.02

Ethnicity

-.25

-2.04*

.04

Education

-.08

-.71

.005

Sexual Orientation

-.07

-.50

.002

Intravenous Drug Use

-.36

-2.95**

.08

T-Cells

-.19

-1.73

.03

HIV Symptom Count

-.08

-.75

.005

Depressive Symptoms

-.23

-2.12*

.04

*p<.05
**p<.01
Analysis of Attenders vs. Nonattenders on an Annual Basis
Since the multiple regression analyses was conducted on a subset of the total sample,
further analysis evaluating factors relating to appointment attendance on an annual basis was
necessary. This will allow for determination regarding the relative contribution (if any) of
significant results found in the multiple regression analysis. To further examine group
differences in attendance by year, chi square analysis was conducted. For the following
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analyses, “attenders” were defined as attending at least 80% of scheduled appointments within
the year. The total sample (N=160) was used to conduct the following analyses. This allows for
an evaluation of factors related to attendanceon an annual basis. Individuals with less than 80%
total attendance were classified as “nonattenders”. Eighty percent adherence has typically been
used as a gold standard to measure “successful adherence” in medication adherence. Because
relatively few studies regarding HIV appointment attendance exist, no prior studies have
classified individuals as “attenders” vs. “nonattenders” using a percentage of total appointments.
Consequently, the known gold standard was utilized for this study. A stricter definition of
adherence would have also significantly reduced sample size and not have allowed for
comparisons between these two groups. Since only three participants were Hispanic and the rest
of the minority sample was African American, ethnicity was grouped as Caucasian and Minority.
Bonferroni corrections were used in interpreting the significance of each chi square test. The
following analyses were interpreted based on an alpha level of .004.
Analysis of Attenders vs. Nonattenders by Ethnicity
The chi-square test of independence was used to determine if attendance to medical
appointments was dependent on demographic group membership for each year of the study.
When expected attendance was compared among Caucasian and Minority participants, chi
square tests were significant for year one, χ2 (df = 1, N = 160) = 10.84, p = .001, and year two,
χ2(df = 1, N = 104) = 15.41, p < .001, but not year three. Thus, Minority participants
demonstrated higher levels of appointment nonattendance than their Caucasian counterparts
during year one and year two. These chi square results can be found in Table 6 – Table 8.
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Table 6. Year One: Chi-square Test of Independence for Attendance: Ethnicity
Variable
Attendance
Yes
No

Caucasian

Minority

χ2

df

Significance

28

31

10.84

1

p = .001

25

76

Table 7. Year Two: Chi-square Test of Independence for Attendance: Ethnicity
Variable
Attendance
Yes
No

Caucasian

Minority

χ2

df

Significance

27

22

15.41

1

p < .001

10

45

Table 8. Year Three: Chi-square Test of Independence for Attendance: Ethnicity
Variable
Attendance
Yes
No

Caucasian

Minority

χ2

df

Significance

17

22

1.71

1

p = .28

9

39

Analysis of Attenders vs. Nonattenders by Gender
The chi-square test of independence was used to determine if attendance to medical
appointments was dependent on gender during each year of the study. When expected
attendance was compared among male and female participants, significant differences were only
noted in year two χ2 (df = 1, N = 104) = 16.36, p < .001, with males being more likely to attend
appointments than males. These Chi square results can be found in Table 9 – Table 11.
Table 9. Year One: Chi-square Test of Independence for Attendance: Gender
Variable
Attendance
Yes
No

Male

Female

χ2

df

Significance

38

21

.56

1

p = .45

21

42

32

Table 10. Year Two: Chi-square Test of Independence for Attendance: Gender
Variable
Male
Female
χ2
Significance
df
Attendance
Yes
No

38

11

59

34

16.36

1

p < .001

Table 11. Year Three: Chi-square Test of Independence for Attendance: Gender
Significance
Variable
Male
Female
χ2
df
Attendance
Yes
No

24

18

28

24

.10

1

p = .75

Analysis of Attenders vs. Nonattenders by Sexual Orientation
The chi-square test of independence was used to determine if attendance to medical
appointments was dependent on sexual orientation. When expected attendance was compared
among participants who identified as heterosexual and homosexual, significant differences were
noted in year two only χ2(df = 1, N =104) = 9.54, p = .002, with participants who were
heterosexual participants being less likely to attend appointments than participants who were
homosexual. These chi square results can be found in Table 12 – Table 14.
Table 12. Year One: Chi-square Test of Independence for Attendance: Orientation
Variable
Heterosexual Homosexual
χ2
Significance
df
Attendance
Yes
No

34

25

68

32

33

1.74

1

p = .19

Table 13. Year Two: Chi-square Test of Independence for Attendance: Orientation
Variable
Heterosexual Homosexual
χ2
Significance
df
Attendance
Yes
No

22

27

41

14

9.54

1

p = .002

Table 14. Year Three: Chi-square Test of Independence for Attendance: Orientation
Significance
Variable
Heterosexual Homosexual
χ2
df
Attendance
Yes
No

24

18

35

17

1.03

1

p = .311

Analysis of Attenders vs. Nonattenders by Intravenous Drug Use History
The chi-square test of independence was used to determine if attendance to medical
appointments was dependent on history of intravenous drug use (IV Drug Use). When expected
attendance was compared among participants with and without a history of intravenous drug use,
no significant differences were noted. These chi square results can be found in Table 15 – Table
17.
Table 15. Year One: Chi-square Test of Independence for Attendance: IV Drug Use
Variable
Attendance
Yes
No

IVDU

No IVDU

χ2

Df

Significance

18

40

.778

1

p = .378

38

62

34

Table 16. Year Two: Chi-square Test of Independence for Attendance: IV Drug Use
Variable

IVDU

No IVDU

χ2

Df

Significance

13

36

1.77

1

p = .183

21

33

Attendance
Yes
No

Table 17. Year Three: Chi-square Test of Independence for Attendance: IV Drug Use
Variable
IVDU
No IVDU
χ2
Significance
df
Attendance
Yes
No

8

34

21

31

4.96

1

p = .026

Analysis of Attenders vs. Nonattenders by Current Substance Abuse
The chi-square test of independence was used to determine if attendance to medical
appointments was dependent on current substance abuse as noted by physicians and nurses
during clinic visits. When expected attendance was compared among participants with and
without current substance abuse, no significant differences were noted in year one or year two.
Because only two participants were noted to have difficulty with substance abuse, analysis of
year three data could not be conducted. These chi square results can be found in Table 18 –
Table 19.
Table 18. Year One: Chi-square Test of Independence for Attendance: Substance Abuse
Variable
Substance
No Substance
χ2
Significance
Df
Abuse
Abuse
Attendance
Yes
4
18
3.83
1
p = .04
No

55

83
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Table 19. Year Two: Chi-square Test of Independence for Attendance: Substance Abuse
Variable
Substance
No Substance
χ2
Significance
Df
Abuse
Abuse
Attendance
Yes
5
44
.28
1
p = .43
No

4
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Analyses of Attrition-Related Variables
The data were examined to determine the frequency of attrition over the three-year study
period and to investigate potential demographic group-related variables. During the first year of
the study 6 participants died (3.8%), 15 participants were lost to follow-up (9.6%), and 7
participants appropriately transferred their care to another medical clinic (4.5%). During the
second year of the study, 9 participants died (7.5%), 21 participants were lost to follow-up
(17.5%), and 3 participants appropriately transferred their care to another medical clinic (2.5%).
During the third year of the study, 1 participant died (.9%), 17 participants were lost to follow-up
(15.9%), and 5 participants appropriately transferred their care to another medical clinic (3.2%).
The presence of current substance abuse steadily declined as the study progressed beginning with
21 participants (13.5%) in year one, and declining to 9 participants (7.5%) in year two and 2
participants (1.9%) in year three. See Table 20 for these results.
Table 20. Percentage of Sample Attrition by Study Year
Death

Lost to Follow-Up

Appropriate Transfer

Year One

3.8% (N=6)

9.6% (N=15)

4.5% (N=7)

Year Two

7.5% (N=9)

17.5% (N=21)

2.5% (N=3)

Year Three

.09% (N=1)

15.9% (N=17)

3.2% (N=5)
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In order to determine if significant group differences occurred in attrition, chi square tests
of independence were conducted. Men were more likely to be lost to follow-up than females in
year one, χ2(df = 1, N = 156) = 5.04, p = .025. Minorities were more likely to be lost-to followup in year two, χ2(df = 1, N = 129) = 6.745 p = .009. Also, having a history of intravenous drug
use in year one made substance abuse in year one of the study more likely χ2(df = 1, N = 154) =
8.14, p = .004. No other significant differences were found between groups (ethnicity, gender,
orientation, intravenous drug use) on attrition related variables.
The largest reason for attrition in the current study was loss to follow up. This indicates
that many participants failed to return to the clinic with no warning and effectively dropped out
of treatment. If these individuals did not seek treatment at other facilities, they may have posed
an increased risk of further transmitting HIV to others. To further examine factors associated
with participants who were lost to follow up in the current study, a multiple regression analysis
was conducted. Demographic factors (gender, ethnicity, age, education, and sexual orientation),
illness related factors (T-cell count, symptoms count), and distress related variables (intravenous
drug use history, current substance abuse, and depressive symptoms) were entered into a
regression equation to determine if these variables significantly predicted individuals who
dropped out of treatment. Separate analyses were conducted for each study year. Significant
results were only noted in year one. The regression revealed that in year one of the study
participants who were of younger age (Beta= -.194), male (Beta=. 362), and demonstrated
increased depressive symptoms (Beta=. 228) were more likely to be lost to follow up (R2 (10,
118) = .17, p = .01). See Table 22 for a summary of these results.
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Table 22. Multiple Regression Analysis: Lost to Follow Up
Squared
Variable

∃

t

Semipartial
Correlation

Age

-.19

-2.05*

.03

Gender

.36

2.98**

.06

Ethnicity

-.21

1.96

.03

Education

.05

.53

.04

Sexual Orientation

-.06

-.46

.001

Intravenous Drug

-.01

-.05

.00006

Use

.06

.60

.003

T-Cells

-.16

-1.6

.02

HIV Symptom

-.23

2.58*

.05

Count
Depressive
Symptoms
*p<.05
**p<.01
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Discussion
The results of the current study did not support the primary hypothesis that coping
strategies would significantly predict appointment attendance above and beyond other
demographic and distress related variables on a long-term basis. Multiple regression analysis
revealed the coping style that participants used to adjust to HIV-related stressors did not impact
their appointment attendance over a three-year follow-up period. Although the study failed to
support the primary hypothesis, important findings were noted. Demographic factors including
ethnicity, history of intravenous drug use, and depressive symptoms predicted future adherence
with medical appointments on a long-term basis. Specifically, minority status, increased
endorsement of depressive symptoms, and a positive history of intravenous drug use was
associated with higher levels of appointment non-attendance. These results must be interpreted
with caution as they were only noted during a regression analysis of a highly selective sample of
individuals who remained in treatment for a three-year time period. Analysis of the entire
sample on an annual basis only showed that ethnicity was an important factor related to
nonattendance in year one and two of the study. Consequently, generalizability of the current
results is limited.
Appointment Attendance
Ethnicity and Appointment Attendance
Ethnicity was predictive of failure to attend HIV clinic appointments for a period of three
years after initial contact with the clinic. Although other studies have noted decreased
appointment attendance among minority individuals (Catz, et al., Israelaski, et. al., 2001;
McClure, et al., 1999), this is the first known study to evaluate the impact of psychosocial factors
in appointment adherence on a long-term basis. The current results add to a growing body of
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literature finding that minority individuals demonstrated reduced attendance to scheduled HIV
clinic appointments. However, none of these studies have investigated the specific variables
associated with minority individuals that lead to decreased appointment adherence. Given that
minority status continues to impact appointment attendance on a long-term basis, research
regarding these issues is necessary. Factors related to socioeconomic status (SES) such as
inadequate financial means, poor access to medical care, limited education, and poor community
support have been found to be important in adherence in other chronic illnesses and may also be
important in individuals with HIV (Rimer, et al., 1996). Since these factors were not part of the
primary hypotheses being evaluated, the current study was unable to adequately examine these
variables. For example, the present sample was comprised of indigent individuals with
approximately 87% of the sample reporting annual incomes at or below $10,000 and did not
allow for analysis of income-related variables. The only other variable related to SES in the
current study included education. Education level was not significantly related to attendance
variables, but was related to increased depressive symptoms.
Depressive Symptoms and Appointment Attendance
Depressive symptoms have been found to negatively impact adherence with HIV
treatment regimens (Bogart, et al., 2000, Catz, et al., 2000; Kalichman et al., 2000; Rabkin &
Chesney, 1999). The current study showed that increased depression at clinic intake was
associated with higher levels of appointment non-attendance over a three year time period. Thus,
increased presence of depressive symptoms may be a risk factor not only for medication
adherence, but also for failing to meet other HIV treatment requirements like appointment
attendance.
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Failure to attend appointments can have serious consequences on overall health and well
being for individuals with HIV (Lucas et al., 1999). Since depression appears to be a major risk
factor for adherence difficulties, HIV clinics should address this issue with all patients. The
results of this study suggest that including a psychometrically sound screening instrument during
initial contact with patients may help identify individuals who are risk for failing to attend
regularly scheduled appointments on a long term basis. This information can be used to develop
targeted interventions aimed at preventing appointment nonadherence. Many clinics already
obtain information concerning depressive symptoms, but may not administer a standardized
scale, which would ensure adequate assessment of depressive symptoms. Screening for
depressive symptoms is straightforward, can be easily included in the intake process, and has the
potential to greatly benefit patients.
Increased depressive symptoms were noted in the current sample. The mean CES-D
score (M=21.89) was above the cutoff score (16) indicating the presence of significantly elevated
depressive symptoms. Although not found in all samples, the current increased level of reported
depressive symptoms in individuals with HIV is consistent with prior literature (Heckman, et al.,
1999; Griffin & Rabkin, 1997). Griffin and Rabkin (1997) noted that increased depressive
symptoms frequently occur in research studies conducted in clinic settings, particularly when the
assessments were obtained at clinic intake. A large amount of variability also existed in this data
(SD=13.04). Thus, the majority of depressive symptoms may have been experienced by certain
segments of the sample. Increased depressive symptoms were associated with individuals who
had decreased levels of education. Consequently, the current results regarding depression and
long-term appointment attendance should be interpreted with caution and future studies
replicating these effects would be useful.

41

Intravenous Drug Use History and Appointment Attendance
A history or intravenous drug abuse emerged as an important predictor of appointment
attendance on a long-term basis. This is consistent with previous literature concerning history of
illicit drug use and appointment attendance (Kissinger, et al., 1995; McClure, et al., 1999). The
current results showed that a history of intravenous drug use remains an important risk factor for
failure to attend appointments even three years after intake into the clinic. This highlights the
importance of obtaining detailed information concerning drug use history, as past substance
abuse is highly associated with continued use during treatment. The longer individuals were in
treatment, the less likely they were to demonstrate current substance abuse. Outside of coping
style, the current study was not specifically designed to evaluate factors related to substance use
that negatively impact appointment attendance. However, the current results suggest that
understanding the relationship between substance abuse and treatment adherence behaviors is
needed. The current results coupled with evidence that substance abuse interferes with
medication adherence suggest that a primary method to increase HIV treatment adherence in
individuals with substance abuse may be to help them reduce or eliminate their substance use
(Eldred et al., 1998).
Coping
Coping and Appointment Attendance
Appointment attendance over a three-year period was negatively associated with
emotion-focused coping including confrontive, self-controlling, accepting responsibility, and
positive reappraisal coping strategies. Of these strategies, a confrontive coping strategy
remained negatively associated with appointment attendance during each year of the study. This
suggests that individuals who handle problems or stressors through destructive or risky means
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are more likely to demonstrated reduced appointment attendance. Other emotion focused coping
appeared to have more of a negative impact on coping during the first year of treatment. These
results were noted during correlational analysis and did not maintain their significance when
demographic, illness-related, and distress-related factors were entered into a multiple regression
analysis.
The current study showed that coping style (emotion-focused vs. problem-focused) did
not significantly impact appointment adherence. However, other studies have found that coping
is an important variable in improving HIV treatment adherence (Singh, 1996, Singh, 1999).
Explanations for the discrepancy of these results must be explored. Prior studies that have noted
the importance of coping in HIV treatment have been conducted with combination medication
regimens. It may be the case that coping strategy is important to medication adherence and not
to appointment attendance. Medication adherence requires continuous effort on a daily basis
from patients; whereas, appointment attendance occurs on an irregular basis and tend to be
scheduled at varying time intervals.
The coping literature suffers from a lack of cohesiveness, with researchers using different
definitions of coping and different measures to assess coping skills. It may be the case that these
variations in methodology also produce variations in research results. The current study
evaluated coping during initial contact with the patient and did not analyze coping on a
longitudinal basis. Although we attempted to stabilize the coping measure by concentrating on
HIV-related stressors, this procedure may not have fully accounted for the dynamic nature of the
coping process. Initial coping strategies may not influence long-term adherence behaviors due to
changes in coping over time. The current study also utilized a situation (i.e., being diagnosed
with HIV and attending treatment) that is perceived as uncontrollable rather than measuring an
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individual’s perception of controllability of HIV-related stressors. Although this is a common
methodological shortcoming in studies of coping, it still does not give us a true indication of the
effects of coping on behavioral aspects of adherence. Ideally, coping should be evaluated
repeatedly over time and include perceptions of the participants perceived controllability over the
stressors (Park, Folkman, & Bostrom, 2001).
Coping and Ethnicity
It was hypothesized that minority individuals would utilize significantly more emotionfocused coping strategies and report increased levels of depression when compared to their
Caucasian counterparts. The current results revealed that minorities utilized emotion-focused
coping strategies more than problem-focused coping strategies. Specifically, minority
participants in this study were more likely to utilize positive reappraisal as a specific coping
strategy. These results are consistent with a growing body of evidence highlighting ethnic
differences in coping with HIV-related stressors (Heckman, et al., 1999; Lesserman, et al., 1992;
Singh et al., 1999).
However, minority individuals (primarily African Americans) did not endorse
significantly increased depressive symptoms when compared to Caucasian participants.
Although, these results differ from some published studies (Leserman et al., 1992; Singh et al.,
1999), they are consistent with at least one other research study that included primarily lowincome African American participants (Heckman et al., 1999). These results suggest that
emotion-focused coping is not inevitably a negative influence on the adjustment process. There
was no evidence in the current study to suggest that problem-focused coping is associated with
decreased endorsement of depressive symptoms. Perhaps other variables such as perceived
controllability or social support that were not specifically evaluated in this study may be utilized
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more frequently by minority individuals. These variables may offer a protective shield or buffer
against psychological distress regardless of type of coping strategy utilized.
Relationship between Coping and Depressive Symptoms
Emotion-focused coping was significantly associated with increased endorsement of
depressive symptoms. Specifically, participants who utilized confrontive, distancing, selfcontrolling, escape-avoidance, and strategies that involved accepting responsibility for being
HIV- positive reported increased depressive symptoms. This suggests that individuals who
respond to the stress associated with being HIV positive with increased hostility, avoidance, selfblame, detachment, and strict regulation of thoughts or emotions may experience increased
emotional distress and depressive symptoms. Again, no protective benefits of problem-focused
coping were noted to be significantly associated with decreased depressive symptoms.
Substance Use and Coping
It was hypothesized that participants with a history of substance abuse would utilize
emotion-focused coping strategies more than problem focused coping strategies. Specifically, it
was expected that participants with a history of substance abuse would utilize significantly more
avoidant coping than participants who had no history of substance abuse. In other populations,
increased use of avoidant coping has been noted in individuals with a history of substance use
(Avants, Warburton, & Margolin, 2000; Belding,et al., 1996). However, the current results
showed that individuals with a history of intravenous drug use utilized significantly more
confrontive coping strategies. These coping strategies include aggressive or hostile efforts to
resolve a stressful situation.
The differences noted in the current study may reflect the use of different assessment
instruments to evaluate coping strategies. These differences may also be related to different
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sampling procedures. Much of the current literature regarding HIV and substance use has been
conducted at outpatient substance abuse treatment centers. The current study consisted of
primarily low-income participants who were receiving treatment at an ambulatory outpatient
HIV clinic associated with a public teaching hospital. It may be that these community samples
are confronted with economical and cultural issues, such as living with community violence, that
differs from participants in other research samples (Plummer & Slane, 1996). Further research
regarding the role of coping in individuals with substance abuse and subsequent impact on
adherence behaviors is needed.
Summary
The primary purpose of the current study was to evaluate the effects of initial coping
strategies on long-term appointment attendance in individuals with HIV. It was predicted that
problem-focused coping would be associated with attending regularly scheduled clinic visits and
emotion-focused coping would be predictive of failure to attend appointments. Attendance
information was retrospectively obtained by reviewing medical records. Multiple regression
analysis revealed that the coping style used by participants did not predict appointment
attendance above and beyond the variance predicted by demographic, illness, and distress related
factors. However, minority status, depressive symptoms, and history of intravenous drug use did
emerge as reliable predictors of failure to attend scheduled clinic appointments over a three-year
follow-up period. These data must be interpreted with caution because the sample included in
the multiple regression bias was a subset of a smaller sample and is subject to selection bias.
However, the strength of this data set is supported by the fact that no dignificant differences
occurred between the total sample and regression sample and no evidence of range restriction
was noted.
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Although further research confirming these results with a broader sample that does not
represent such a large selection bias is needed, these results suggest that information that is easily
obtained during the patient’s initial contact with the clinic may be critical in determining who is
most at risk for failing to attend scheduled clinic appointments on a long-term basis. Since,
attendance at clinic appointments is necessary to receive appropriate HIV medical care and to
ensure treatment success, identification of variables related to non-attendance is important.
Further research should evaluate the specific variables associated with poor appointment
attendance among minority individuals.
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Appendix A
Demographics Questionnaire
Subject #:

Intake Date:

DOB:

EKL#:

Age:

Date of HIV Diagnosis:

Sex:

Male

Female

Race: Caucasian African American
Income (yearly): <$10,000

Hispanic

$10-20,000

Other:

$20-30,000

$30-40,000

>$40,000

Education (Highest Grade Completed):
Marital Status: Single

Married

Sexual Orientation: Homo/Bisexual

Divorced

Widowed

Other:

Heterosexual

Substance Use:
IV Drug Use:

Yes (current/past)

No

IV Drug Use Partner Yes

No

Blood Recipient

No

Yes

What Year?

Other Drug Use in Last 6 Months
Marijuana Y N

Cocaine/Crack Y N

Speed/Crystal Meth Y N
Tobacco Use Y N

LSD/Acid Y N

Rush/Ethyl/Poppers Y N

How Much Per Day?

ETOH Consumption: Y N
How Much? <7 oz week

>7oz week

Average Number (daily):

Antiretroviral Medications: Y N Names:

Date Started:

T-cell Counts: CD4
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Appendix B
Ways of Coping Questionnaire: Coping Subscales
____________________________________________________________________
Coping Subscale
Description
____________________________________________________________________
Confrontive Coping

Aggressive or hostile efforts to resolve
the stressful situation

Self-Controlling

Efforts to regulate thoughts, behaviors,
or emotions

Distancing

Cognitive efforts to detach from the
stressful situation or minimize its impact

Seeking Social Support

Efforts to find emotional, social, and
educational support from others

Accepting Responsibility

Recognizing personal role in the
situation and attempts to correct any
problems

Escape-Avoidance

Cognitive and behavioral efforts to
escape or avoid the stressful situation.

Planful Problem Solving

Purposeful and well thought out efforts
to solve the problem at hand

Positive Reappraisal

Efforts to create positive meaning by
focusing on positive aspects of stressful
situation (e.g., chance for personal
growth). Religious reappraisal is also
included here.
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Appendix C
Symptom Checklist for HIV Infection
1. Oral candidiasis (ever)
2. Lymphadenopathy/thrush (by examination, currently)
3. Nonallergic body rash (history of, during last three months)
4. Shingles (history of, during last three months)
5. Sinusitis (history of, during last three months)
6. Oral leukoplakia (by examination, currently)
7. Fever (history of, during last three months)
8. Night sweats (history of, during last three months)
9. Rashing or scaling around eyes (history of, during last three months)
10. Diarrhea (history of, during last three months)
11. Psoriasis (history of, during last three months)
12. Shortness of breath (history of, during last three months)
13. Easy bruising (history of, during last three months)
14. Sore throat (history of, during last three months)
15. Persistent cough (history of, during last three months)
16. Meningitis (history of, during last three months)
17. Hair loss (history of, during last three months)
18. Pneumonia (history of, during last three months)
19. Herpes (oral/genital) (ever)
20. Weight loss (more than 10%) (history of, during last three months)
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Appendix D
Informed Consent
Louisiana State University Medical Center in New Orleans
1. Study Title: The impact of stress, mood, and social support on HIV disease status
2. Performance Sites: Earl K. Long Medical Center, Baton Rouge, Louisiana.
3. Names and Telephone Numbers of Investigators:
For 24-hour access, please call ….. (504) 358-1105
Phillip J. Brantley, Ph.D. …………(504) 358-1105
Glenn N. Jones, Ph.D. ……………(504) 358-1105
Jennifer McClure …………………(504) 358-1105
Sheryl Catz, M.A. ………………..(504) 358-3927
4. Purpose of the Study: This is a research study designed to investigate how stress, mood, and
social support impact the health status of patients with HIV (Human Immunodeficiency Virus).
Aside from participating in a brief psychological/medical history and filling out questionnaires
(e.g., on stress, HIV symptoms, mood, and social support) about every six months, research
subjects will not be treated any differently than other patients at the clinic. The laboratory
analysis of immune functioning is part of the medical assessment that all patients undergo
routinely.
5. Subject Inclusion Criteria: Individuals between the ages of 18 and 65 are eligible to
participate in the study. Participants must be HIV positive.
6. Subject Exclusion Criteria: Individuals will not be eligible to participate in the study if they
are unable to read or comprehend the nature of the questionnaires for any reason (e.g., illiteracy).
7. Description of the Study: During a routine clinic appointment, when laboratory analysis of
immune functioning has been scheduled, patients at the clinic will be informed of the study by an
attending nurse or physician. If a patient volunteers to participate, he/she will sign the informed
consent. A graduate student in Clinical Psychology at Louisiana State University will conduct an
interview to gather a brief medical and psychological history. Subjects then will complete
questionnaires (e.g., on stressful life events, social support, mood, coping, and HIV symptoms).
Subjects allow the experimenter access to their medical records to obtain laboratory reports and
other medical information (e.g., medication usage, onset of symptoms, number of visits to the
clinic). At or before regularly scheduled follow-up clinic appointments, participants will be
reminded of the project and again asked to complete the questionnaires.
8. Benefits to Subject: Subjects will receive $5.00 following each participation in the study.
Other potential benefits may include increased knowledge about HIV and strategies to cope with
the disease.
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9. Risks to Subject: There are no known major physical, psychological, or social risks
associated with participation in the study. However, there may be unforeseen risks associated
with participation. Lesser risks can be explained if the subjects desire this information. Subjects
should not expect their medical conditions to improve by participation in this study. If the
subjects wish, the experimenter can provide a referral for additional assistance.
10. Alternatives to Participation in the Study: Participation is voluntary. Subjects who choose
not to participate will attend their clinic appointments as usual.
11. Subject Removal: There are no foreseeable circumstances under which eligible subjects
would be removed from the study against their wishes. Subjects who fail to return for their
regularly scheduled clinic appointments (e.g., for over a year) may be removed from the study.
12. Subject’s Right to Refuse to Participate or Withdraw: Study subjects may refuse to
participate or withdraw from the study at any time without jeopardizing, in any way, their
medical treatment at this institution in the present or the future. Should significant new findings
develop during the course of the research which may relate to the subject’s willingness to
continue participation, that information will be provided to the subject.
13. Subject’s Right to Privacy: The results of the study may be published, released to a funding
agency or presented in a scholarly fashion (e.g., at a conference). The privacy and confidentiality
of subjects will be protected, and they will not be identified in any way.
14. Release of Information: The medical records related to the study are available to the
experimenter. By agreeing to participate in this research study and by signing the consent form,
the subject gives permission for his/her attending medical staff to release relevant medical
information (e.g., diagnoses, medications, rate of clinic attendance) to the experimenter.
15. Financial Information: A) Participation in this study will not result in any extra charges
above and beyond those routinely incurred by patients with similar illnesses. B) The costs of
study related and unforeseen complications must be met by subjects. C) Subject Payment:
Subjects will be paid $5.00 for participation in the study.
16. Signatures: The study has been discussed with me and all my questions have been answered.
I understand that additional questions regarding the study should be directed to investigators
listed on page 1 of this consent form. I understand that if I have questions about subjects’ rights,
or other concerns, I can contact Dr. Perry, G. Rigby, Chancellor, at (504) 568-4801. I agree with
the terms above and acknowledge I have been given a copy of the consent form.
_______________________________________________
Signature of Subject
______________________________________________
Signature of Witness

60

_________
Date
_________
Date

Vita
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undergraduate studies in 1995 at Southeastern Louisiana University where she graduated
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61

